The Role of FTO in the Regulation of T Cell Function and Immune Infiltration, and Its Potential Applications in Immunotherapy

Xiang Li; Yanru Lv; Yanrong Hao

doi:10.54097/c90f1489

Authors

Xiang Li
Yanru Lv
Yanrong Hao

DOI:

https://doi.org/10.54097/c90f1489

Keywords:

FTO, m6A Modification, T Cell Exhaustion, Immune Infiltration, Immunotherapy, Tumor Microenvironment

Abstract

The Fat Mass and Obesity-Associated Protein (FTO), a primary N6-methyladenosine (m6A) demethylase, has emerged as a critical regulator of T cell function, immune infiltration, and immunotherapy efficacy. This review synthesizes current evidence on FTO's enzymatic mechanisms, its impact on T cell differentiation and exhaustion, and its role in shaping the tumor immune microenvironment (TIME). We explore how FTO-mediated m6A demethylation modulates key transcripts involved in T cell survival , effector function, and metabolic pathways. Additionally, we examine FTO's influence on immune cell infiltration patterns across cancers, including hepatocellular carcinoma (HCC) and glioblastoma, and its contribution to immunosuppressive niches. The review highlights therapeutic strategies targeting FTO—such as small-molecule inhibitors and PROTAC degraders—and their synergistic potential with immune checkpoint inhibitors (ICIs), radiotherapy, and targeted agents. Finally, we address unresolved questions regarding FTO substrate specificity, context-dependent functions, and challenges in clinical translation, emphasizing opportunities for advancing cancer immunotherapy through epigenetic reprogramming.

Downloads

Download data is not yet available.

References

[1] Feng Lili, Du Rongrong, Chang Baitong, Li Min, Tian Jie, Wang Shengjun Multilevel regulation of N6-methyladenosine RNA modifications: Implications in tumorigenesis and therapeutic opportunities. [J].Genes & Diseases, 2022, 10(5):1969-1981. DOI: 10.1016/j.gendis.2022.08.018.

[2] Liu Lina, Wang Yuwei, Wu Jie, Liu Jingwen, Qin Zongchang, Fan Hong N6-Methyladenosine: A Potential Breakthrough for Human Cancer. [J].Molecular therapy. Nucleic acids, 2019, 19:804-813. DOI:10.1016/j.omtn.2019.12.013.

[3] Zhang Xiao, Wei Lian-Huan, Wang Yuxin, Xiao Yu, Liu Jun, Zhang Wei, Yan Ning, Amu Gubu, Tang Xinjing, Zhang Liang, Jia Guifang Structural insights into FTO's catalytic mechanism for the demethylation of multiple RNA substrates. [J].PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116(8):2919-2924. DOI:10.1073/pnas.1820574116.

[4] Huang Hao, Li Xinlu, Luo Jinlian, Gao Chuan, Yang Mengjie, Xu Jin, Xie Ting, Chen Zhi, Wang Donghai, Wang Yuan, Li Hua-Bing, Huang Jinyan, Liu Yu, Zhang Haojian, Ntziachristos Panagiotis, Zhao Yun, Qing Guoliang, Liu Hudan FTO regulates ELK3-mediated metabolic rewiring and represents a unique therapeutic target in T cell leukemia. [J].Science advances, 2025, 11(22):eadq3052. DOI:10.1126/ sciadv. adq3052.

[5] Chen Ao, Zhang Vanilla Xin, Zhang Qingyang, Sze Karen Man-Fong, Tian Lu, Huang Hongyang, Wang Xia, Lee Eva, Lu Jingyi, Lyu Xueying, Lee Man-Fong Joyce, Wong Chun Ming, Ho Daniel Wai-Hung, Ng Irene Oi-Lin Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma. [J].GUT, 2024, 74(1):90-102. DOI:10.1136/gutjnl-2024-3319 03.

[6] Kang Kuan, Lin Xin, Chen Pan, Liu Huai, Liu Feng, Xiong Wei, Li Guiyuan, Yi Mei, Li Xiayu, Wang Hui, Xiang Bo T cell exhaustion in human cancers. [J].BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879(5):189162. DOI: 10.1016/j.bbcan.2024.189162.

[7] Li Yixing, Wu Kejing, Quan Weili, Yu Lin, Chen Shuang, Cheng Chao, Wu Qijia, Zhao Shuhong, Zhang Yi, Zhou Lei The dynamics of FTO binding and demethylation from the m6A motifs. [J].RNA Biology, 2019, 16(9):1179-1189. DOI: 10. 1080/15476286.2019.1621120.

[8] Guo Wenhui, Wang Zhao, Zhang Yajiao, Li Yashu, Du Qian, Zhang Tiantian, Hu Jin, Yao Yingpeng, Zhang Jiarui, Xu Yingdi, Cui Xiao, Sun Zhen, You Menghao, Yu Guotao, Zhang Haojian, Du Xuguang, Xu Jingyu, Yu Shuyang Mettl3-dependent m6A modification is essential for effector differentiation and memory formation of CD8+ T cells. [J].Science Bulletin, 2023, 69(1):82-96. DOI:10.1016/j. scib. 2023.11.029.

[9] Sun Lina, Zhang Tianzhe, Ge Yao, Yao Zhihong, Su Yanhong, Wang Qianhao, Chen Yang, He Boxiao, Ding Renyi, Zhang Cangang, Lan Linbo, Liu Ruonan, Ping Huanxin, Zhang Dan, Shi Lin, Zhou Xiaobo, Jia Xiaoxuan, Sun Chenming, Liang Lingli, Zhang Lianjun, Zhang Baojun FTO controls CD8+ T cell survival and effector response by modulating m6A methylation of Fas. [J].Cell death & disease, 2025, 16(1):301. DOI:10.1038/s41419-025-07606-z.

[10] Jiang Qi, Wang Xin, Wu Yingping, Cui Dawei The m6A Modification in T Helper Cells Regulates the Pathogenesis of Autoimmune Diseases. [J].Journal of inflammation research, 2025, 18:13159-13172. DOI:10.2147/JIR.S537243.

[11] Zhou Huimin, Mao Lingxiang, Xu Huaxi, Wang Shengjun, Tian Jie The functional roles of m6A modification in T lymphocyte responses and autoimmune diseases. [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 65:51-60. DOI:10.1016/j.cytogfr.2022.04.004.

[12] Yao Zhihong, Sun Lina, Gao Yang, Su Yanhong, He Boxiao, Ge Yao, Yang Chen, Jia Xiaoxuan, Jiao Anjun, Sun Chenming, Zhang Baojun The m6A demethylase FTO controls Th1 differentiation and immunity against infections. [J].Molecular immunology, 2025, 183:172-181. DOI: 10.1016/j. molimm. 2025. 05.004.

[13] Sun Qinli, Dong Chen Regulators of CD8+ T cell exhaustion. [J]. NATURE REVIEWS IMMUNOLOGY, 2025, 26(2):129-151. DOI:10.1038/s41577-025-01221-x.

[14] Su Rui, Dong Lei, Li Yangchan, Gao Min, Han Li, Wunderlich Mark, Deng Xiaolan, Li Hongzhi, Huang Yue, Gao Lei, Li Chenying, Zhao Zhicong, Robinson Sean, Tan Brandon, Qing Ying, Qin Xi, Prince Emily, Xie Jun, Qin Hanjun, Li Wei, Shen Chao, Sun Jie, Kulkarni Prakash, Weng Hengyou, Huang Huilin, Chen Zhenhua, Zhang Bin, Wu Xiwei, Olsen Mark J, Müschen Markus, Marcucci Guido, Salgia Ravi, Li Ling, Fathi Amir T, Li Zejuan, Mulloy James C, Wei Minjie, Horne David, Chen Jianjun Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. [J].CANCER CELL, 2020, 38(1):79-96.e11. DOI:10.1016/j.ccell.2020.04.017.

[15] Hu Zhekai, Li Yuqing, Yuan Weihao, Jin Lijian, Leung Wai Keung, Zhang Chengfei, Yang Yanqi N6-methyladenosine of Socs1 modulates macrophage inflammatory response in different stiffness environments. [J].International journal of biological sciences, 2022, 18(15):5753-5769. DOI:10.7150/ ijbs.74196.

[16] Wang Zhigang, Qi Yuanbo, Feng Yonghua, Xu Hongen, Wang Junxiang, Zhang Luyu, Zhang Jie, Hou Xinyue, Feng Guiwen, Shang Wenjun The N6-methyladenosine writer WTAP contributes to the induction of immune tolerance post kidney transplantation by targeting regulatory T cells. [J]. LABORATORY INVESTIGATION, 2022, 102(11):1268-1279. DOI:10.1038/s41374-022-00811-w.

[17] Lu Shuang, Wei Xingyu, Zhu Huan, Hu Zhi, Zheng Meiling, Wu Jiali, Zhao Cheng, Yang Shuang, Feng Delong, Jia Sujie, Zhao Hongjun, Zhao Ming m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus. [J]. MOLECULAR MEDICINE, 2023, 29(1):46. DOI: 10. 1186/ s10020-023-00643-4.

[18] Wang Huamin, Hu Xiang, Huang Mingyan, Liu Juan, Gu Yan, Ma Lijia, Zhou Qi, Cao Xuetao Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation. [J]. Nature communications, 2019, 10(1):1898. DOI:10.1038/s41467-019-09903-6.

[19] Sun Chongqi, Wang Jian, Li Huixing, Liu Luyao, Lin Yu, Zhang Ling, Zu Xianglong, Zhu Yizhi, Shu Yongqian, Shen Dong, Wang Qiong, Liu Yiqian METTL14 regulates CD8+T-cell activation and immune responses to anti-PD-1 therapy in lung cancer. [J]. World journal of surgical oncology, 2024, 22(1):128. DOI:10.1186/s12957-024-03402-9.

[20] Tay Tristan, Bommakanti Gayathri, Jaensch Elizabeth, Gorthi Aparna, Karapa Reddy Iswarya, Hu Yan, Zhang Ruochi, Doshi Aatman S, Tan Sin Lih, Brucklacher-Waldert Verena, Prickett Laura, Kurasawa James, Overstreet Michael Glen, Criscione Steven, Buenrostro Jason Daniel, Mele Deanna A Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay. [J].Cell reports. Medicine, 2024, 5(11):101804. DOI:10.1016/j.xcrm.2024.101804.

[21] Pei Mengmiao, Chai Wenjia, Wang Xiaolin, Duan Yanlong, Wang Hui, Xi Yue, Mou Wenjun, Wang Wei, Chen Xi, Zhang Hui, Li Qiliang, Song Wenqi, Wang Huanmin, Ma Xiaoli, Gui Jingang The transcription factor TOX is involved in the regulation of T-cell exhaustion in neuroblastoma. [J]. IMMUNOLOGY LETTERS, 2022, 248:16-25. DOI: 10. 1016/ j. imlet.2022.06.004.

[22] Huang Yue, Su Rui, Sheng Yue, Dong Lei, Dong Ze, Xu Hongjiao, Ni Tengfeng, Zhang Zijie Scott, Zhang Tao, Li Chenying, Han Li, Zhu Zhenyun, Lian Fulin, Wei Jiangbo, Deng Qiangqiang, Wang Yungui, Wunderlich Mark, Gao Zhiwei, Pan Guoyu, Zhong Dafang, Zhou Hu, Zhang Naixia, Gan Jianhua, Jiang Hualiang, Mulloy James C, Qian Zhijian, Chen Jianjun, Yang Cai-Guang Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. [J].CANCER CELL, 2019, 35(4):677-691.e10. DOI:10.1016/ j.ccell. 2019.03.006.

[23] Huangfu Ning, Li Fang, Wang Chenqiu, Jin Shouyi, Zheng Xiaoya, Wang Yingsong, Fang Tianxiang, Shen Jiaxi, Yu Yanan, Jian Liguo, Qi Datun, Zhao Wenting, Jian Dongdong METTL3/RBM15 augments the stability of Kdm6b mRNA and promotes STAT1-mediated macrophage activation and atherosclerosis. [J].EXPERIMENTAL AND MOLECULAR MEDICINE, 2025, 57(12):2916-2929. DOI:10.1038/s12276-025-01594-y.

[24] Pan Yimin, Xiao Kai, Li Yue, Li Yuzhe, Liu Qing RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma [J]. Frontiers in Oncology, 2021, 11. DOI:10. 3389/ fonc.2021.632934.

[25] Pan Yimin, Xiao Kai, Li Yue, Li Yuzhe, Liu Qing RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma. [J]. Frontiers in oncology, 2021, 11:632934. DOI: 10.3389/fonc.2021.632934.

[26] Zhang Junhao, Li Guoxi, Wu Runqiu, Shi Lin, Tian Cong, Jiang Hongyan, Che Hongyu, Jiang Yongang, Jin Zhiyong, Yu Rutong, Liu Xuejiao, Zhang Xu The m6A RNA demethylase FTO promotes radioresistance and stemness maintenance of glioma stem cells. [J]. Cellular signalling, 2025, 132:111782. DOI:10. 1016/j.cellsig.2025.111782.

[27] Xu Chen, Jiang Liangjun, Lu Xianzhou, Li Wei The FTO-YTHDF2 axis drives immune evasion and tumor progression in hepatocellular carcinoma via m6A-dependent FLAD1 regulation. [J]. JOURNAL OF MOLECULAR HISTOLOGY, 2025, 56(5):267. DOI:10.1007/s10735-025-10557-6.

[28] Zhang Jiayu, Meng Xianpeng, Zhao Bozhi, Wang Hongyu, Hu Qunyu, Wang Songhe, Zhou Linlin, Zhang Yinghui, Zhang Dongwei FTO promotes the progression of triple-negative breast cancer by regulating the m6A methylation of NFKBIE. [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25(1):320. DOI:10.1007/s10238-025-01872-z.

[29] Li Gaofeng, Fu Qiru, Liu Cong, Peng Yuxi, Gong Jun, Li Shilan, Huang Yan, Zhang Haiyuan The regulatory role of N6-methyladenosine RNA modification in gastric cancer: Molecular mechanisms and potential therapeutic targets. [J].Frontiers in oncology, 2022, 12:1074307. DOI:10. 3389/ fonc. 2022.1074307.

[30] Zeng Hua, Xu Junmei, Wu Rui, Wang Xin, Jiang Yaqing, Wang Qing, Guo Jiali, Xiao Feng FTO alleviated ferroptosis in septic cardiomyopathy via mediating the m6A modification of BACH1. [J].BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870(7):167307. DOI:10.1016/j.bbadis.2024.167307.

[31] Wang Zhenyu, Sun Huamin, Zhu Hua, Gu Donghua, Chen Xinfeng, Pan Yongsheng, Zheng Bing, Yang Dongrong Demethylase FTO inhibits the development of prostate cancer by upregulating EGR2 expression in an m6A manner. [J]. TURKISH JOURNAL OF BIOLOGY, 2022, 46(6):426-438. DOI:10.55730/1300-0152.2629.

[32] Lai Huan, Hu Nan, Zhang Miao, Jiang Weiwei, Han Yiqian, Mao Chenxi, Zhou Kangjie, Zhang Jingzhou, Hong Yidong, Wu Fenglei FTO is Associated with Patient Prognosis and Immune Infiltrates in Gastric Cancer and Regulates TGF-β Expression. [J].COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2025, 28(11):1911-1926. DOI: 10. 2174/0113862073299882240530051559.

[33] Dong Ze, Huang Yue, Xia Wenyang, Liao Yonggang, Yang Cai-Guang A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present. [J].Expert opinion on therapeutic patents, 2025, 35(6):533-542. DOI:10. 1080/13543776.2025.2477482.

[34] Liu Lu, Qiu Yuanlai, Suo Yuying, Tong Siyao, Wang Yiqing, Zhang Xi, Chen Liang, Huang Yue, Zhou Huchen, Zhou Hu, Dong Ze, Yang Cai-Guang Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy. [J].Acta Pharmaceutica Sinica B, 2024, 14(12):5382-5392. DOI:10.1016/j.apsb.2024.07.016.

[35] Ji Lu, Pu Leighton, Wang Jinglong, Cao Hongbin, Melemenidis Stavros, Sinha Subarna, Guan Li, Laseinde Eyiwunmi E, von Eyben Rie, Richter Sara A, Nam Jin-Min, Kong Christina, Casey Kerriann M, Graves Edward E, Frock Richard L, Le Quynh Thu, Rankin Erinn B FTO inhibition enhances the therapeutic index of radiation therapy in head and neck cancer. [J].JCI insight, 2025, 10(11). DOI:10.1172/ jci. insight.184968.

[36] Saad Abdulaziz Ahmed A, Ge Lichen, Wang Haoran, Xia Yan, Li Jianing, Qiao Shiyao, Yi Cheng, Wang Xiansong, Wang Zhaotong, Zhou Dan, Wang Hongsheng Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells. [J].International Journal of Biological Sciences, 2025, 21(15):7063-7085. DOI:10.7150/ijbs.117999.

[37] Zhang Bo, Tao Baorui, Li Yitong, Yi Chenhe, Lin Zhifei, Ma Yue, Han Jiahao, Shao Weiqing, Chen Zhenmei, Lin Jing, Chen Jinhong Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. [J]. European Journal of Internal Medicine, 2022, 111:37-46. DOI: 10.1016/j.ejim.2022.12.025.

[38] Kudo Masatoshi Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma. [J].Liver Cancer, 2024, 13(3):227-234. DOI:10.1159/ 0005 38558.

[39] Huang Hao, Wang Yinu, Kandpal Manoj, Zhao Guangyuan, Cardenas Horacio, Ji Yanrong, Chaparala Anusha, Tanner Edward J, Chen Jianjun, Davuluri Ramana V, Matei Daniela FTO-Dependent N 6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. [J].CANCER RESEARCH, 2020, 80(16):3200-3214. DOI: 10.1158/0008-5472.CAN-19-4044.

[40] Tarullo Marco, Fernandez Rodriguez Guillermo, Iaiza Alessia, Venezia Sara, Macone Alberto, Incocciati Alessio, Masciarelli Silvia, Marchioni Marcella, Giorgis Marta, Lolli Marco Lucio, Fornaseri Federico, Proietti Ludovica, Grebien Florian, Rosignoli Serena, Paiardini Alessandro, Rotili Dante, Mai Antonello, Bochenkova Elena, Caflisch Amedeo, Fazi Francesco, Fatica Alessandro Off-Target Inhibition of Human Dihydroorotate Dehydrogenase (hDHODH) Highlights Challenges in the Development of Fat Mass and Obesity-Associated Protein (FTO) Inhibitors. [J].ACS Pharmacology & Translational Science, 2024, 7(12):4096-4111. DOI:10.1021/ acsptsci. 4c00533.

[41] Deng Xiaolan, Su Rui, Stanford Savanna, Chen Jianjun Critical Enzymatic Functions of FTO in Obesity and Cancer. [J].Frontiers in endocrinology, 2018, 9:396. DOI: 10.3389/ fendo. 2018.00396.

[42] Xiao Yang, Jiang Tianyu, Qi Xinyi, Zhou Jinfeng, Pan Tingli, Liao Qichao, Liu Siqi, Zhang Hao, Wang Jiale, Yang Xinzhen, Yu Lin, Liang Yuehui, Liang Xue, Batsaikhan Batbold, Damba Turtushikh, Batchuluun Khongorzul, Liang Yunxiao, Zhang Ying, Li Yixing, Zhou Lei PROTAC-mediated FTO protein degradation effectively alleviates diet-induced obesity and hepatic steatosis. [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 285:138292. DOI: 10. 1016/j.ijbiomac.2024.138292.

[43] Shishodia Shifali, Demetriades Marina, Zhang Dong, Tam Nok Yin, Maheswaran Pratheesh, Clunie-O'Connor Caitlin, Tumber Anthony, Leung Ivanhoe K H, Ng Yi Min, Leissing Thomas M, El-Sagheer Afaf H, Salah Eidarus, Brown Tom, Aik Wei Shen, McDonough Michael A, Schofield Christopher J Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. [J].Journal of medicinal chemistry, 2021, 64(22):16609-16625. DOI:10.1021/acs. jmedchem. 1c0 1204.